VivoSeq
Immunology

Alopecia Areata

85

Pipeline Programs↗

36

Active Trials↗

39

Companies Involved↗

Alopecia Areata is a moderately active landscape with 85 programs across 39 companies. The most active players are Forte Biosciences, Inc., HCW Biologics, Iovance Biotherapeutics, Inc.. 17 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

43/100

Mech. Concentration

15/100

Completion Rate

81/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Forte Biosciences, Inc.

1 program

Phase 1H

HCW Biologics

1 program

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 1V

Validus Pharmaceuticals

1 program

Phase 1GSK logo

GSK

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical10

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Botulinum Toxin Type a

Revance Therapeutics, Inc.

Alefacept

Astellas

Vit D

Post Graduate Institute of Medical Education and Research, Chandigarh

Niosome Minoxidil

Assiut University

Phase 112

Aldesleukin

Iovance Biotherapeutics, Inc.

Metformin

EMD Serono

Pentoxifylline

Validus Pharmaceuticals

Mometasone Furoate

Novartis

Cyclosporine

Novartis

Phase 233

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Secukinumab

Novartis

Tralokinumab

LEO Pharma

Etrasimod

Pfizer

Abatacept

Bristol-Myers Squibb

Phase 313

Baricitinib

Eli Lilly

Ritlecitinib

Pfizer

Upadacitinib

AbbVie

PF-06651600

Pfizer

IL2

Assistance Publique - Hôpitaux de Paris

Approved17

Latanoprost

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Bexarotene

Bausch Health Americas, Inc.

Delgocitinib

Alnylam Pharmaceuticals

Simvastatin

Organon and Co

Platelet Rich Plasma

Zagazig University

Analysis

Modality Breakdown

89%

Small molecule

94 of 106 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody66%Protein / enzyme55%Vaccine1<1%

Small molecule leads; the ring shows all 106 classified programs, each share of the total. Modality classified for 96% of 114 pipeline programs.

Analysis

Trial Status

133

clinical trials

Completed63 · 47%
Recruiting21 · 16%
Unknown status19 · 14%
Terminated10 · 8%
Active, not recruiting8 · 6%
Not yet recruiting7 · 5%
Other5 · 4%

Clinical Trials

Trial Activity

133 trials

A Study of LAD603 in Adults With Alopecia Areata
Recruiting·—·Phase 2·NCT07311564·136 enrolled
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Recruiting·AbbVie logoAbbVie·Phase 3·NCT07023302·123 enrolled
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Recruiting·FForte Biosciences, Inc.·Phase 1·NCT07205159·32 enrolled
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Recruiting·EErasmus Medical Center·Phase 4·NCT07381556·50 enrolled
Intralesional Cyclosporine for Alopecia Areata
Recruiting·UUniversity of California, Davis·Phase 1·NCT07029204·12 enrolled
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Recruiting·Pfizer logoPfizer·Phase 3·NCT07029828·140 enrolled
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Recruiting·Pfizer logoPfizer·Phase 3·NCT06873945·550 enrolled
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
Recruiting·Pfizer logoPfizer·N/A·NCT07152119·3,000 enrolled
Dupilumab in the Treatment of Pediatric Alopecia Areata
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05866562·76 enrolled
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT05723198·595 enrolled
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Recruiting·UUniversidad Autonoma de Nuevo Leon·N/A·NCT06564805·30 enrolled
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Recruiting·Sun Pharmaceutical Industries, Inc. logoSun Pharmaceutical Industries, Inc.·Phase 3·NCT07133308·355 enrolled
Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
Recruiting·ZZagazig University·N/A·NCT06327581·88 enrolled
Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata
Recruiting·NNEXTGEN Bioscience·Phase 2·NCT06104839·96 enrolled
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Recruiting·Pfizer logoPfizer·Phase 3·NCT07029711·225 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)